The COVID-19 pandemic achieved in two years what might have taken twenty under normal circumstances: complete, large-scale validation of mRNA vaccine technology as a safe and effective platform. Before 2020, mRNA vaccines had never been approved for any human disease, having been limited by challenges in mRNA stability, delivery, and immunogenicity. The Pfizer-BioNTech and Moderna COVID vaccines — administered to nearly 5 billion people — provided an unprecedented human safety and efficacy dataset. The consequence is now unfolding: a broad pipeline of mRNA vaccines against influenza, RSV, CMV, HIV, cancer, and rare genetic diseases is advancing faster than any previous vaccine development period in history.
mRNA Flu Vaccines: The End of Egg-Based Manufacturing?
Seasonal influenza vaccines have historically been manufactured in fertilized chicken eggs — a process that takes 6 months, cannot be rapidly updated when strains drift, and yields vaccines with reduced effectiveness (55–60% in good-match years) due to egg-adaptation mutations in hemagglutinin antigens. Moderna's mRNA-1010 (quadrivalent seasonal influenza mRNA vaccine) completed Phase 3 trials in 2023–2024 demonstrating superior immunogenicity against H3N2 strains — the most clinically important influenza type and the greatest limitation of egg-based vaccines. The mRNA platform enables strain update in weeks rather than months, theoretically allowing strain selection closer to the season and potentially real-time updates during a rapidly evolving outbreak.
Personalized mRNA Cancer Vaccines: mRNA-4157
Perhaps the most exciting application is personalized neoantigenic cancer vaccines. Tumors accumulate somatic mutations — generating mutant proteins called neoantigens — that are unique to each patient's cancer. Moderna and Merck's mRNA-4157/V940 identifies each patient's tumor neoantigens through whole-exome sequencing, computationally selects the 34 most immunogenic, synthesizes a personalized mRNA vaccine within approximately 6 weeks, and trains the immune system to recognize and attack cells expressing those neoantigens. In the Phase 2b KEYNOTE-942 trial with pembrolizumab for resected high-risk melanoma, the combination reduced recurrence/death by 44% versus pembrolizumab alone at 2.5-year follow-up — a landmark result prompting breakthrough therapy designation and Phase 3 trials across multiple solid tumor types.
RSV mRNA Vaccines
Moderna's mRNA-1345 RSV vaccine for adults 60+ completed Phase 3 trials demonstrating 83.7% efficacy against lower respiratory tract disease — comparable to Pfizer's Abrysvo and GSK's Arexvy that achieved approval in 2023 via recombinant protein platforms. The mRNA platform advantage will likely emerge in pediatric RSV — maternal vaccination programs and potentially direct infant vaccination — where dose-sparing and rapid manufacturing for outbreak-driven campaigns may prove decisive.
CMV: Addressing a Common Unmet Need
Cytomegalovirus (CMV) — estimated to affect 50–80% of adults in developed countries by age 40 — causes serious disease in immunocompromised patients (transplant recipients, HIV patients), congenitally infected newborns, and represents the most common non-genetic cause of pediatric hearing loss. Moderna's mRNA-1647 CMV vaccine demonstrated 68.7% efficacy in Phase 2b trials — the most effective CMV vaccine candidate ever tested, entering Phase 3 enrollment in 2025. A successful CMV vaccine is expected to prevent 30,000 cases of congenital CMV per year in the US alone. Healthcare facilities can find relevant diagnostic equipment in our catalog.
